SOPHiA GENETICS SA (SOPH) stock
Close on Nov 16, 2026Market cap $509.54MP/E –Yield –
SOPHiA GENETICS SA grew revenue 18.6% to $77.27M over fiscal 2025. Free cash flow was -$36.47M. At the latest close the market valued the company at $509.54M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $509.54M
- P/E ratio
- –
- Price to sales
- 6.59
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -7.16%
Fundamentals
- Revenue
- $77.27M
- Net income
- -$79.00M
- EPS, diluted
- -$1.17
- Free cash flow
- -$36.47M
- Diluted shares
- 74M
Trading
- Previous close
- $8.21
- Open
- $8.07
- Day's range
- $7.40 – $8.13
- Volume
- 782,480
- Average volume (20 days)
- 669,399
- 52-week range
- $3.83 – $8.98
- RSI (14 days)
- 49.5
- Volatility (1 year)
- 62.7%
- Relative volume
- 1.34×
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | SOPH | S&P 500 | Difference | SOPH per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +10.5% | -3.1% | +13.6 pts | ||
| 3 months | -0.8% | -4.5% | +3.7 pts | ||
| Year to date | +59.3% | +9.4% | +50.0 pts | ||
| 1 year | +72.6% | +11.3% | +61.3 pts | ||
| 3 years | +103.3% | +70.4% | +32.9 pts | +26.7% | +19.4% |
| 5 years | -52.0% | +68.6% | −120.6 pts | -13.7% | +11.0% |
Eight years at a glance
Fiscal years 2018 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases SOPHiA GENETICS filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About SOPHiA GENETICS
Services-Computer Processing & Data Preparation
SOPHiA GENETICS is a healthcare software company that develops a cloud-based analytics platform for data-driven medicine. Its core product, SOPHiA DDM, standardizes and analyzes complex genomic and multimodal health data for applications across oncology, rare diseases, cardiology, and neurology. The company also offers the Alamut interpretation software, the SOPHiA CarePath multimodal module, and biopharma solutions for clinical trials and companion diagnostics. Its customers include academic and community hospitals, reference and specialty laboratories, and biopharmaceutical firms.
Company profile, executives and historySOPHiA GENETICS stock: common questions
What is SOPHiA GENETICS's stock price?
SOPH closed at $7.44 on Nov 16, 2026, down 9.38% on the day. Over the past 52 weeks it traded between $3.83 and $8.98.
What is SOPHiA GENETICS's market cap?
SOPHiA GENETICS was worth $509.54M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is SOPH's P/E ratio?
SOPHiA GENETICS lost money over fiscal 2025 (diluted EPS -$1.17), so it has no meaningful P/E ratio.
How much revenue does SOPHiA GENETICS make?
SOPHiA GENETICS reported revenue of $77.27M for fiscal 2025, up 18.6% from a year earlier.
Does SOPHiA GENETICS pay a dividend?
No. SOPHiA GENETICS has not paid a cash dividend over the last twelve months.
How has SOPH stock performed over the past year?
Including dividends, SOPH returned +72.6% over the past year, against +11.3% for the S&P 500.
How many SOPH shares are sold short?
1M shares were sold short at the latest FINRA report, 1.88% of the float, or 2.6 days of average trading volume.
Who are SOPHiA GENETICS's competitors?
Companies most similar to SOPHiA GENETICS by business, industry and size include VERI, INOD, CTW, INFQ, BIRD.
See a number that looks wrong?